Calluna Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of various diseases. The company leverages its proprietary technology platform to discover and advance new treatments, with an emphasis on oncology and other therapeutic areas with significant unmet medical needs.

Calluna Pharmaceuticals, Inc.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal.

We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases. 


Calluna Pharma

Today, on World Kidney Day, we aim to raise awareness about Chronic Kidney Disease (CKD), impacting over 850 million people globally and leading to more than 3.1 million deaths in 2019. Over the last three decades, CDK treatment efforts have centered on preparing for and delivering kidney replacement therapies. However, recent therapeutic breakthroughs offer the opportunity to prevent or delay disease progression and mitigate complications such as cardiovascular disease and kidney failure, ultimately improving patient outcomes.

At Calluna Pharma we are developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.

🚀 At the forefront of our portfolio is CAL101, a monoclonal antibody that neutralizes the bioactivity of S100A4, a DAMP protein implicated in serious and life-threatening diseases such as chronic kidney disease, severe (steroid insensitive) asthma, and pulmonary fibrosis. In chronically diseased tissues, S100A4’s inappropriate upregulation switches self-limiting tissue repair responses into chronic activation of inflammatory signaling pathways and sustained fibrogenesis.

With CAL101, we aim to shift the paradigm, offering hope to patients grappling with serious and potentially life-threatening diseases such as chronic kidney disease.

If you'd like to learn more about our work and therapeutic pipeline, visit our website: https://lnkd.in/e37y2VKy

#WorldKidneyDay2024 #Immunology #PrecisionMedicine #ChronicKidneyDisease #CKD

Calluna Pharma is attending #BioEuropeSpring, March 18-20! 

Our CEO, John Montana, and Chief Medical Officer & Co-Founder, Jonas Hallén, are going to be in Barcelona next week for one of Europe's premier springtime partnering events, featuring multiple networking opportunities and a carefully curated program providing insights into the latest trends, challenges, and opportunities in the sector.  

Find out more, and join us here: https://lnkd.in/ee6-YHVa 

Our CEO John Montana spoke with BioWorld News following the announcement of our official company launch and €75 million (US$81 million) Series A financing to advance neutralizing antibodies targeting proinflammatory molecules that drive inflammatory and fibrotic diseases. In the interview John outlines how the funding will be used over the next three years to drive phase IIa data generation across three indications. 
 
➡️CAL-101, targeting S100A4, is currently in a Phase Ib trial, with results anticipated in the first half of this year. Future plans include Phase IIa proof-of-concept (PoC) studies addressing fibrotic and chronic inflammatory diseases.

➡️CAL-102, targeting oxidised phospholipids (OxPL), is progressing through preclinical development for myocardial infarction induced reperfusion injury, with Phase I development slated for 2025. The funding will propel its progression to generate Phase IIa clinical PoC data in a comparable timeframe to the CAL101 clinical readouts.

➡️CAL-103 will also progress to a Phase Ib biomarker data readout in an inflammatory indication by mid 2026.
 
Read the full interview here: https://rb.gy/pyapsv

 #Biotech #Biopharma #Immunology #Clinical #Innovation

‘What will shape the biotech industry in 2024?’🔍

Our CEO, John Montana, recently spoke to Labiotech.eu about his 2024 predictions for biotech. 

One thing John mentioned is that after a challenging year, companies with emerging clinical pipelines poised to reach clinical PoC within their current funding round, are well placed for further investment – as such companies would not only be seen as attractive candidates for potential M&A, but also, assuming favorable market conditions, IPO. Speaking about the importance of diversified and relevant company assets, John added that “Success also hinges on a diversified portfolio, which mitigates investor single asset risk. Additionally, strategic alignment with diseases of high pharma interest, opens doors for licensing opportunities providing access to non-dilutive funding and potential acquisition. With a focus on immunology, and a pipeline of first-in-class clinical antibodies, Calluna Pharma, addresses these key benchmarks for 2024 and beyond” 

Read more here: https://bit.ly/42beMZz 

#Biotech #Innovation #Biopharma #Immunology #Clinical

Just ahead of the official company launch announcement, our CEO, John Montana, spoke to Endpoints News’ Anna Brown about the successful merger and Calluna’s robust clinical pipeline. 

As part of the interview John commented on the future of the company: “Things look very exciting for the new company going forward. That’s why the current investors have decided to not only merge the companies but provide it with a significant runway,”

Want to read more? Find the exclusive interview here: https://bit.ly/3Hzon2U

#DrugDevelopment #Clinical #Biologics #Immunology 

COM:CALLUNAPHARMA

Calluna Pharmaceuticals, Inc.